JS-004
- Generic Name
- JS-004
Combination of Toripalimab and JS004 Therapy for ccRCC
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT06690697
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer Extensive StageSmall Cell Lung Cancer Recurrent
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 100
- Registration Number
- NCT06648200
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 117
- Registration Number
- NCT06370754
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
- Conditions
- Limited Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 30
- Registration Number
- NCT06256237
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
- Conditions
- Stage III Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 124
- Registration Number
- NCT05891080
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
- Conditions
- Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT05427396
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- Conditions
- Metastatic Solid TumorAdvanced Unresectable Solid Tumor
- Interventions
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- TopAlliance Biosciences
- Target Recruit Count
- 499
- Registration Number
- NCT04137900
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The Ohio State University Wexner Medical Center The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.